<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-42967" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Terazosin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yang</surname>
            <given-names>Cheng H.</given-names>
          </name>
          <aff>USHEC - San Antonio</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raja</surname>
            <given-names>Avais</given-names>
          </name>
          <aff>University of Western States, Portland, Oregon</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cheng Yang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Avais Raja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-42967.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Terazosin is a medication used in the management and treatment of benign prostatic hyperplasia and essential hypertension. Terazosin is a long-acting, selective alpha-1 adrenergic receptor antagonist. This activity reviews the indications, action, and contraindications for Terazosin as a valuable agent in managing benign prostatic hyperplasia, essential hypertension, and nephrolithiasis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pharmacokinetics and pharmacodynamics of terazosin with emphasis on the context of patient safety.</p></list-item><list-item><p>Identify the indications for terazosin therapy.</p></list-item><list-item><p>Review the mechanism of action of terazosin that leads to its therapeutic effect.</p></list-item><list-item><p>Summarize interprofessional team strategies regarding the appropriate uses of terazosin to enhance patient safety and comfort while minimizing the risk of adverse events.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42967">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-42967.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Terazosin was approved by the Food and Drug Administration (FDA) in 1987 initially as a treatment for hypertension.<xref ref-type="bibr" rid="article-42967.r1">[1]</xref>&#x000a0;Later in 1993, it was approved as a treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia.<xref ref-type="bibr" rid="article-42967.r2">[2]</xref> The role of pharmacologic therapy in distal urinary tract stones is currently a focus of research, with terazosin and other alpha-1 antagonists under consideration for potential therapeutic value in addition to its traditionally accepted symptomatic relief effects.<xref ref-type="bibr" rid="article-42967.r3">[3]</xref>&#x000a0;</p>
        <p>Off-label&#x000a0;uses for terazosin currently being studied include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>In more recent literature, terazosin, among other agents of its class been the subject of research as an off-label agent for the use of medical expulsive therapy (MET), a form of medical management for distal ureteral calculi.<xref ref-type="bibr" rid="article-42967.r4">[4]</xref><xref ref-type="bibr" rid="article-42967.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Alleviation of nightmares associated with post-traumatic stress disorder (PTSD)<xref ref-type="bibr" rid="article-42967.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Antihidrotic in patients who have hyperhidrosis related to selective serotonin reuptake inhibitor (SSRI) use<xref ref-type="bibr" rid="article-42967.r6">[6]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic prostatitis/chronic pelvic pain syndrome<xref ref-type="bibr" rid="article-42967.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Urethritis associated with radiation therapy<xref ref-type="bibr" rid="article-42967.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Idiopathic oligozoospermia<xref ref-type="bibr" rid="article-42967.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-42967.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Terazosin is a selective, quinazoline-derived post-synaptic alpha-1 antagonist.<xref ref-type="bibr" rid="article-42967.r10">[10]</xref>&#x000a0;Alpha-1 adrenergic receptors subdivide into alpha-1A, alpha-1B, and alpha-1D.<xref ref-type="bibr" rid="article-42967.r11">[11]</xref> Due to their nature as adrenergic receptors, they are members of the G-protein coupled receptor category. Terazosin is a competitive antagonist at these receptors, similar to other selective alpha-1 antagonists such as prazosin and doxazosin, notably at alpha-1A, which comprises the majority of alpha receptors in the urothelium.<xref ref-type="bibr" rid="article-42967.r12">[12]</xref> The alpha-1 receptors are commonly located diffusely in smooth muscle tissue, including vascular smooth muscle, sphincter smooth muscle, and urinary bladder smooth muscle.<xref ref-type="bibr" rid="article-42967.r13">[13]</xref></p>
        <p>Alpha-1 adrenergic receptors are also present in many other organ systems, including the central nervous system, endocrine system, and gastrointestinal system. The primary anti-hypertensive action occurs by blocking vascular smooth muscle in the arterioles. The anti-obstructive urinary tract effects result from smooth muscle relaxation in the ureters, bladder, and urethral sphincter.<xref ref-type="bibr" rid="article-42967.r14">[14]</xref>&#x000a0;Terazosin's exertion of&#x000a0;an anti-nightmare effect does not have a clearly elucidated mechanism. However, a possible explanation could be&#x000a0;due to the presence of presynaptic alpha-adrenergic receptors in the central nervous system.</p>
      </sec>
      <sec id="article-42967.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Terazosin is available in the US in oral capsule formulation in the form of a hydrochloride salt, available in 1 mg, 2 mg, 5 mg, and 10 mg formulations. For the FDA approved indications of hypertension and benign prostatic hyperplasia, the dosing route, frequency, and amount&#x000a0;are as follows:</p>
        <p>
<bold>Hypertension</bold>
</p>
        <p>The initial dose&#x000a0;is 1 mg to 10 mg orally daily, titrated upwards as needed to a maximum of 20 mg daily. Considered a second-line agent due to adverse effects, additional consideration as an agent if the patient also experiences lower urinary tract symptoms associated with benign prostatic hyperplasia.<xref ref-type="bibr" rid="article-42967.r15">[15]</xref><xref ref-type="bibr" rid="article-42967.r16">[16]</xref></p>
        <p>
<bold>Benign Prostatic Hyperplasia</bold>
</p>
        <p>The initial dose is 1 mg to 10 mg orally at bedtime, titrated upwards as needed based upon patient response up to 20 mg daily in 1 or 2 divided doses.<xref ref-type="bibr" rid="article-42967.r17">[17]</xref></p>
        <p>For Non-FDA approved indications,<bold>&#x000a0;</bold>including medical expulsive therapy (MET), chronic prostatitis, hyperlipidemia, urethritis, hyperhidrosis, and oligospermia:</p>
        <p>
<bold>Medical Expulsive Therapy for Distal Ureteral Calculi</bold>
</p>
        <p>2 mg to 10 mg orally at bedtime. Most studies have indicated usage of 2 mg to 5 mg, and only rarely have 10 mg doses been cited. For MET, the typical duration of terazosin is for up to 2 weeks, and the patient may discontinue therapy following the expulsion of the stone.<xref ref-type="bibr" rid="article-42967.r4">[4]</xref></p>
        <p>
<bold>Chronic Prostatitis/Chronic Pelvic Pain Syndrome</bold>
</p>
        <p>1 mg to 5 mg orally daily for 14 weeks. Terazosin demonstrated effectiveness in a study comparing alpha-antagonist na&#x000ef;ve patients with chronic prostatitis/chronic pelvic pain syndrome with a placebo.<xref ref-type="bibr" rid="article-42967.r7">[7]</xref></p>
        <p>
<bold>Hyperlipidemia/Hypercholesterolemia</bold>
</p>
        <p>5 mg, 10 mg, or 20 mg orally daily. Studies demonstrating the lipid-lowering effects were subject to confounding factors due to titration of drug dosing to diastolic blood pressure or meeting the maximum (20 mg) dosage for terazosin. Additionally, there have not been studies to demonstrate a mortality benefit, as seen for other lipid-lowering drugs.<xref ref-type="bibr" rid="article-42967.r18">[18]</xref><xref ref-type="bibr" rid="article-42967.r19">[19]</xref></p>
        <p>
<bold>Idiopathic Oligozoospermia</bold>
</p>
        <p>2 mg orally daily. One clinical study by Gregoriou et al. demonstrated a statistically significant improvement in spermatozoa count and seminal fluid volume after treatment with six months of terazosin. However, the study noted no change in the mean percentage of abnormal spermatozoa and also did not detect any significant difference in pregnancy rates.<xref ref-type="bibr" rid="article-42967.r9">[9]</xref></p>
        <p>
<bold>Urethritis associated with Radiotherapy in Prostate Cancer</bold>
</p>
        <p>2 mg to 6 mg orally daily. One study from Zelefsky et al. suggests an improvement in urinary tract symptoms associated with radiotherapy for localized prostate cancer.<xref ref-type="bibr" rid="article-42967.r20">[20]</xref></p>
        <p>
<bold>Antidepressant-induced Excessive Sweating</bold>
</p>
        <p>1 mg to 6 mg orally daily. A recent clinical trial demonstrated a positive response to hyperhidrosis associated with selective serotonin reuptake inhibitor use.<xref ref-type="bibr" rid="article-42967.r3">[3]</xref></p>
      </sec>
      <sec id="article-42967.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Terazosin is generally well-tolerated. Many adverse effects of terazosin are explainable due to its blockade of alpha-1 adrenergic receptors.<xref ref-type="bibr" rid="article-42967.r16">[16]</xref><xref ref-type="bibr" rid="article-42967.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Statistically significant adverse effects associated with terazosin detected in placebo-controlled trials listed in the FDA database include dizziness, headache, weakness, postural hypotension, and nasal congestion.<xref ref-type="bibr" rid="article-42967.r21">[21]</xref><xref ref-type="bibr" rid="article-42967.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>First-dose syncope is rare and may be mitigated by bedtime use. Orthostatic hypotension is common and should merit strong consideration when prescribing terazosin.<xref ref-type="bibr" rid="article-42967.r23">[23]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>According to the FDA, post-marketing surveys also found priapism, atrial fibrillation, anaphylaxis, and intraoperative floppy iris syndrome associated with terazosin use, though instances of such occurrences were extremely rare.</p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Terazosin has been used in many patients on various concomitant medicines; while these interactions are not studied extensively, no interactions are observed.</p>
      </sec>
      <sec id="article-42967.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The only absolute contraindication to the usage of terazosin is allergy or hypersensitivity to the medication. Relative contraindications include usage in geriatric populations due to the potential for patient harm associated with syncope and/or postural hypotension due to terazosin use,&#x000a0;patients with heart failure, and general intolerance of the adverse effects associated with terazosin.<xref ref-type="bibr" rid="article-42967.r24">[24]</xref> It is important to note that in&#x000a0;geriatric&#x000a0;patient populations, the occurrence of syncope or orthostatic hypotension can lead to falls, which are associated with increased mortality, morbidity, loss of functional capacity, and&#x000a0;institutionalization for diagnostic workup/rehabilitation related to the syncope.<xref ref-type="bibr" rid="article-42967.r25">[25]</xref></p>
        <p>While terazosin is not&#x000a0;contraindicated for use in pediatric populations, caution is advised due to limited data available regarding the use of&#x000a0;the drug in children. However, there are&#x000a0;small studies of safe usage in children without adverse outcomes.<xref ref-type="bibr" rid="article-42967.r26">[26]</xref><xref ref-type="bibr" rid="article-42967.r27">[27]</xref></p>
        <p>
<bold>Warnings</bold>
</p>
        <p>
<bold>Prostatic Cancer</bold>
</p>
        <p>BPH and prostate carcinoma can cause many similar symptoms, and both diseases usually co-exist. Hence, patients thought to have benign prostatic hyperplasia should be tested before starting terazosin to exclude the carcinoma of the prostate.</p>
        <p>
<bold>Intraoperative Floppy Iris Syndrome (IFIS)</bold>
</p>
        <p>During cataract surgery, IFIS has been observed in some patients treated with alpha-1 blockers presently or in the past. Therefore, the ophthalmologist should consider possible modifications of surgical techniques, such as using iris dilator rings, iris hooks, or viscoelastic substances. There is no benefit of stopping terazosin before cataract surgery.</p>
      </sec>
      <sec id="article-42967.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The use of terazosin does not require plasma/blood drug level monitoring. However, after the first dose, vital orthostatic signs should be obtained to exclude postural hypotension. If used for hypertension, orthostatic blood pressures may be checked regularly during the titration interval to confirm efficacy.<xref ref-type="bibr" rid="article-42967.r1">[1]</xref> If used for lower urinary tract symptoms associated with benign prostatic hyperplasia, standard clinical assessment of patients may determine efficacy.<xref ref-type="bibr" rid="article-42967.r5">[5]</xref></p>
      </sec>
      <sec id="article-42967.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdose of terazosin may lead to hypotension, and standard life-support protocols should be in place for instances of hemodynamic instability. There are no antidotes for terazosin toxicity specifically. Vasopressors may be used to support physiologic blood pressure parameters in the event of terazosin overdose. Terazosin is long-acting, with an elimination half-life of approximately 12 hours, and is highly protein-bound. Elimination is via renal excretion (40%) and via excretion of feces (60%).<xref ref-type="bibr" rid="article-42967.r28">[28]</xref></p>
      </sec>
      <sec id="article-42967.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Medications are crucial components of the practice of medicine. In addition to procedural treatments, medications represent an essential aspect of therapy delivery. However, the process of&#x000a0;delivering medication to a patient involves a complex interplay between interprofessional healthcare team members&#x000a0;from several disciplines.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>A qualified physician or mid-level practitioner (NP or PA) must prescribe the medication with appropriate knowledge and assessment of the medication's efficacy and safety profiles according to the patient's demographics, comorbidities, and clinical needs.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The pharmacist who receives the prescription must verify that the dosage prescribed is appropriate and is responsible for communicating with the provider should any mistake or unsafe prescription be discovered and check for potential drug-drug interactions.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The pharmacy technician assisting the pharmacist is encouraged to aid in this role and remain vigilant when physically placing the pills in a bottle and ensuring the label is clear and correct.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The nurse is responsible for administrating the medication to the patient requires vigilance and awareness of the potential hypotension associated with Terazosin and should be meticulous in their measurement of vital orthostatic signs after administration.</p>
          </list-item>
          <list-item>
            <p>A medical assistant may also&#x000a0;assist in measuring vital signs and could be the first person to discover medication safety issues.</p>
          </list-item>
          <list-item>
            <p>The patient and/or their caregiver are the crucial final step in the process, verbalizing any questions or concerns they may have regarding the use of the prescribed medication and signs/symptoms for which they should be vigilant.</p>
          </list-item>
        </list>
        <p>Though Terazosin is relatively contraindicated in geriatric populations, it may still prove to be a useful drug that treats multiple comorbidities at once to limit polypharmacy.<xref ref-type="bibr" rid="article-42967.r29">[29]</xref>&#x000a0;[Level 3]&#x000a0;Terazosin is mainly prescribed for patients with hypertension and BPH.<xref ref-type="bibr" rid="article-42967.r30">[30]</xref><xref ref-type="bibr" rid="article-42967.r31">[31]</xref>&#x000a0; The patient and the rest of the healthcare team, including their physician/mid-level, pharmacy team, and the nursing team, should remain vigilant and aware of the possibility of hypotension or arrhythmia associated with terazosin use. With this type of interprofessional team approach, there can be a maximal therapeutic benefit with minimal adverse events. [Level 5]</p>
      </sec>
      <sec id="article-42967.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42967">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/42967/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=42967">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-42967.s11">
        <title>References</title>
        <ref id="article-42967.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Itskovitz</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.</article-title>
            <source>Clin Ther</source>
            <year>1994</year>
            <season>May-Jun</season>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>490</fpage>
            <page-range>490-504</page-range>
            <pub-id pub-id-type="pmid">7923316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>alpha-Blocker Therapy: Current Update.</article-title>
            <source>Rev Urol</source>
            <year>2005</year>
            <volume>7 Suppl 8</volume>
            <issue>Suppl 8</issue>
            <fpage>S34</fpage>
            <page-range>S34-42</page-range>
            <pub-id pub-id-type="pmid">16985889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghaleiha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahidi</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Afzali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matinnia</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized controlled trial.</article-title>
            <source>Int J Psychiatry Clin Pract</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-7</page-range>
            <pub-id pub-id-type="pmid">22731399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sivaramakrishnan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of alpha blockers in medical expulsive therapy for ureteral stones: a mixed treatment network meta-analysis and trial sequential analysis of randomized controlled clinical trials.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-307</page-range>
            <pub-id pub-id-type="pmid">29334287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preminger</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Tiselius</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Assimos</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Alken</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Buck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gallucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knoll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lingeman</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Nakada</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Pearle</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sarica</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>T&#x000fc;rk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>JS</given-names>
              </name>
              <collab>EAU/AUA Nephrolithiasis Guideline Panel</collab>
            </person-group>
            <article-title>2007 guideline for the management of ureteral calculi.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>178</volume>
            <issue>6</issue>
            <fpage>2418</fpage>
            <page-range>2418-34</page-range>
            <pub-id pub-id-type="pmid">17993340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detweiler</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pagadala</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Candelario</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Detweiler</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lutgens</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center.</article-title>
            <source>J Clin Med</source>
            <year>2016</year>
            <month>Dec</month>
            <day>16</day>
            <volume>5</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">27999253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheah</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Liong</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Teh</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Khor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Yap</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>169</volume>
            <issue>2</issue>
            <fpage>592</fpage>
            <page-range>592-6</page-range>
            <pub-id pub-id-type="pmid">12544314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zelefsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ginor</surname>
                <given-names>RX</given-names>
              </name>
              <name>
                <surname>Fuks</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Leibel</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1999</year>
            <month>Oct</month>
            <day>01</day>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>567</fpage>
            <page-range>567-70</page-range>
            <pub-id pub-id-type="pmid">10524407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregoriou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vitoratos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Papadias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gargaropoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Konidaris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giannopoulos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chryssicopoulos</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of idiopathic oligozoospermia with an alpha-blocker: a placebo-controlled double-blind trial.</article-title>
            <source>Int J Fertil Womens Med</source>
            <year>1997</year>
            <season>Sep-Oct</season>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>301</fpage>
            <page-range>301-5</page-range>
            <pub-id pub-id-type="pmid">9406835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piascik</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Alpha1-adrenergic receptors: new insights and directions.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>298</volume>
            <issue>2</issue>
            <fpage>403</fpage>
            <page-range>403-10</page-range>
            <pub-id pub-id-type="pmid">11454900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Taylor</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Alpha-Adrenergic Receptors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30969652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sagalowsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pettinger</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Renal alpha-1 and alpha-2 adrenergic receptors: biochemical and pharmacological correlations.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1981</year>
            <month>Nov</month>
            <volume>219</volume>
            <issue>2</issue>
            <fpage>400</fpage>
            <page-range>400-6</page-range>
            <pub-id pub-id-type="pmid">6270306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langer</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>History and nomenclature of alpha1-adrenoceptors.</article-title>
            <source>Eur Urol</source>
            <year>1999</year>
            <volume>36 Suppl 1</volume>
            <fpage>2</fpage>
            <page-range>2-6</page-range>
            <pub-id pub-id-type="pmid">10438241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyncl</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of terazosin.</article-title>
            <source>Am J Med</source>
            <year>1986</year>
            <month>May</month>
            <day>23</day>
            <volume>80</volume>
            <issue>5B</issue>
            <fpage>12</fpage>
            <page-range>12-9</page-range>
            <pub-id pub-id-type="pmid">2872801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1269</fpage>
            <page-range>1269-1324</page-range>
            <pub-id pub-id-type="pmid">29133354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titmarsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monk</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.</article-title>
            <source>Drugs</source>
            <year>1987</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>461</fpage>
            <page-range>461-77</page-range>
            <pub-id pub-id-type="pmid">2885169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paick</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.</article-title>
            <source>BJU Int</source>
            <year>2006</year>
            <month>May</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>1017</fpage>
            <page-range>1017-23</page-range>
            <pub-id pub-id-type="pmid">16643483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effect of terazosin on serum lipids.</article-title>
            <source>Am J Med</source>
            <year>1986</year>
            <month>May</month>
            <day>23</day>
            <volume>80</volume>
            <issue>5B</issue>
            <fpage>82</fpage>
            <page-range>82-5</page-range>
            <pub-id pub-id-type="pmid">2872813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.</article-title>
            <source>Int J Occup Environ Health</source>
            <year>2012</year>
            <season>Jan-Mar</season>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-8</page-range>
            <pub-id pub-id-type="pmid">22550699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Rutks</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Terazosin for benign prostatic hyperplasia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2002</year>
            <issue>4</issue>
            <fpage>CD003851</fpage>
            <pub-id pub-id-type="pmid">12519611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.</article-title>
            <source>Br J Pharmacol</source>
            <year>2007</year>
            <month>May</month>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-34</page-range>
            <pub-id pub-id-type="pmid">17351661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapple</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.</article-title>
            <source>Rev Urol</source>
            <year>2005</year>
            <volume>7 Suppl 4</volume>
            <issue>Suppl 4</issue>
            <fpage>S22</fpage>
            <page-range>S22-30</page-range>
            <pub-id pub-id-type="pmid">16986051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Mey</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>alpha(1)-blockers for BPH: are there differences?</article-title>
            <source>Eur Urol</source>
            <year>1999</year>
            <volume>36 Suppl 3</volume>
            <fpage>52</fpage>
            <page-range>52-63</page-range>
            <pub-id pub-id-type="pmid">10559631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rafanelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iacomelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brunetti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ceccofiglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marchionni</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Fall prevention in the elderly.</article-title>
            <source>Clin Cases Miner Bone Metab</source>
            <year>2013</year>
            <month>May</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-5</page-range>
            <pub-id pub-id-type="pmid">24133524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cain</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Herndon</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rink</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Alpha blocker therapy for children with dysfunctional voiding and urinary retention.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>170</volume>
            <issue>4 Pt 2</issue>
            <fpage>1514</fpage>
            <page-range>1514-5; discussion 1516-7</page-range>
            <pub-id pub-id-type="pmid">14501648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Austin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Homsy</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Masel</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cain</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rink</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>162</volume>
            <issue>3 Pt 2</issue>
            <fpage>1064</fpage>
            <page-range>1064-7</page-range>
            <pub-id pub-id-type="pmid">10458432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somberg</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Achari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laddu</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.</article-title>
            <source>Am Heart J</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>122</volume>
            <issue>3 Pt 2</issue>
            <fpage>901</fpage>
            <page-range>901-5</page-range>
            <pub-id pub-id-type="pmid">1678920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maher</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hanlon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hajjar</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Clinical consequences of polypharmacy in elderly.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-65</page-range>
            <pub-id pub-id-type="pmid">24073682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lloyd</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chilton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kaisary</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.</article-title>
            <source>Br J Urol</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>70 Suppl 1</volume>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">1281727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42967.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oelke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Becher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Castro-Diaz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chartier-Kastler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wagg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wehling</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).</article-title>
            <source>Age Ageing</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>745</fpage>
            <page-range>745-55</page-range>
            <pub-id pub-id-type="pmid">26104505</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
